Clinical Trial Update: Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine [Phase 3]

View source ↗

Summary

Phase 3 trial in infants demonstrates non-inferiority, persistence, and immunogenicity of the Hib-MenC vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Infection
• Meningitis Caused By Neisseria Meningitidis

Drugs mentioned

• Hib-MenC vaccine (Haemophilus influenzae type b and Neisseria meningitidis serogroup C conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Status: COMPLETED